NEW YORK (GenomeWeb News) — Share in Genomic Health were down 4.85 percent, or $1.15, at $22.57,  in mid-afternoon trading today after Lehman Brothers cut the company’s market rating to ‘equal weight’ from ‘overweight.’
 
According to Reuters, an analyst at the investment bank said he expects the company’s share price to fall if the US Food and Drug Administration enacts regulations that would make it more difficult for the company to sell its Oncotype Dx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.